Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Harvard-MIT Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Adv Wound Care (New Rochelle). 2021 Sep;10(9):503-528. doi: 10.1089/wound.2020.1167. Epub 2020 Jul 7.
Nonhealing wounds have been the subject of decades of basic and clinical research. Despite new knowledge about the biology of impaired wound healing, little progress has been made in treating chronic wounds, leaving patients with few therapeutic options. Diabetic ulcers are a particularly common form of nonhealing wound. Recently, investigation of therapeutic nucleic acids (TNAs), including plasmid DNA, small interfering RNA, microRNA mimics, anti-microRNA oligonucleotides, messenger RNA, and antisense oligonucleotides, has created a new treatment strategy for chronic wounds. TNAs can modulate the wound toward a prohealing environment by targeting gene pathways associated with inflammation, proteases, cell motility, angiogenesis, epithelialization, and oxidative stress. A variety of delivery systems have been investigated for TNAs, including dendrimers, lipid nanoparticles (NPs), polymeric micelles, polyplexes, metal NPs, and hydrogels. This review summarizes recent developments in TNA delivery for therapeutic targets associated with chronic wounds, with an emphasis on diabetic ulcers. Translational potential of TNAs remains a key challenge; we highlight some drug delivery approaches for TNAs that may hold promise. We also describe current commercial efforts to locally deliver nucleic acids to modulate the wound environment. Localized nucleic acid delivery holds promise for the treatment of nonhealing chronic wounds. Future efforts to improve targeting of these nucleic acid therapies in the wound with both spatial and temporal control through drug delivery systems will be crucial to successful clinical translation.
慢性难愈合创面一直是数十年来基础和临床研究的主题。尽管人们对创伤愈合受损的生物学有了新的认识,但在治疗慢性创面方面几乎没有取得进展,这使得患者的治疗选择有限。糖尿病溃疡是一种特别常见的难愈合创面。最近,对治疗性核酸(TNAs)的研究,包括质粒 DNA、小干扰 RNA、miRNA 模拟物、抗 miRNA 寡核苷酸、信使 RNA 和反义寡核苷酸,为慢性创面的治疗创造了一种新的策略。TNAs 可以通过靶向与炎症、蛋白酶、细胞迁移、血管生成、上皮化和氧化应激相关的基因途径,调节创面朝向有利于愈合的环境。已经研究了多种用于 TNAs 的递送系统,包括树枝状大分子、脂质纳米颗粒(NPs)、聚合物胶束、多聚物复合物、金属 NPs 和水凝胶。本综述总结了与慢性创面相关的治疗靶点的 TNA 递呈的最新进展,重点介绍了糖尿病溃疡。TNAs 的转化潜力仍然是一个关键挑战;我们强调了一些可能有前途的 TNAs 药物递送方法。我们还描述了目前局部递送核酸以调节创面环境的商业努力。局部核酸递送有望治疗难愈合的慢性创面。未来通过药物递送系统在空间和时间上对这些核酸疗法进行靶向的努力,对于成功的临床转化至关重要。